
Langis Michaud, OD, MSc, FAAO, FSLS, FBCLA, FEAOO, emphasized that every staff member should play a role in myopia management during his presentation at Optometry's Meeting 2025.

Langis Michaud, OD, MSc, FAAO, FSLS, FBCLA, FEAOO, emphasized that every staff member should play a role in myopia management during his presentation at Optometry's Meeting 2025.

The Innovation Hub was split into 3 panel discussions on assessing future health through AI-enabled tools, addressing patient workflow challenges through AI, and enhancing treatment through new technologies.

Lifitegrast 5.0% significantly improves clinical signs and biomarkers in dry eye disease, demonstrating effective results within 12 weeks of treatment.

Optometrists learn to recognize and manage pediatric dry eye and myopia, emphasizing proactive care and lifestyle changes for better outcomes.

Karen R. Hoffman, OD, speaks on her AOA 2025 poster, which details a case series on fitting patients with complex corneal conditions with Zenlens (Bausch + Lomb).

Connecting with colleagues, taking courses, and gathering insight for Optometry Times.

Andrew E. Chan, OD, and Daisy Chan, OD, FAAO, discussed microplastic toxicity in the eye at Optometry's Meeting in Minneapolis, and focused on risks associated with long-term contact lens wear and topical therapies.

The company is producing 53% of its eyewear frames from sustainable materials, according to VSP's 2024 Impact Report.

Ashley Mills, CEO of The Vision Council, gives insight into the decision to move to a flagship annual meeting and shares the vision for the meeting going forward.

The expansion includes community health centers in the greater Boston area and Rhode Island.

ST-100 shows promise as a fast-acting treatment for dry eye disease, offering rapid relief and unique collagen repair mechanisms.

Vision Expo, which has been traditionally split into regional East and West meetings, will transition to a single annual meeting that will rotate locations.

The PanOptix Pro lens is available in Canada through Alcon in the single-use Clareon AutonoMe preloaded delivery system.

A $2.5 million endowment establishes the Herbert Simon Chair in Glaucoma Research and Innovation, advancing treatments and research led by renowned glaucoma researcher Alon Harris, PhD, MS, FARVO.

Johnson & Johnson introduces Acuvue Oasys MAX 1-Day multifocal toric lenses, the first and only daily disposable contact lens for astigmatism and presbyopia.

Walkable communities could aid in reduction of type 2 diabetes.

The report examined the most common contact lens searches via Google auto-complete results, 65% of which were reported as purchase driven.

Catch up on the top stories in optometry during the week of June 16-June 20.


A recent $1 million gift will aid in broadening access to emotional support services, including social workers, peer connections, and multimedia content include videos and podcasts.

The Ontario Health Coalition has gathered evidence such as proof of payment and patient reports from 50 patients for the formal complaint.

Priya S. Vakharia, MD; and Deepak Sambhara, MD, FASRS, provide tips to ensure effective comanagement between retina specialists, optometrists, and ophthalmologists.


A study reveals a genetic link between instant coffee consumption and increased risk of dry age-related macular degeneration, urging caution for high-risk individuals.

Embracing new technology is good for patients and provides protection against malpractice claims.

The report categorizes research into 7 categories: sex, gender, and hormones; epidemiology; pathophysiology; tear film; pain and sensation; iatrogenic; and clinical trial design.

The 128th AOA Congress and 57th AOSA conference will be held in Minneapolis, Minnesota, and will feature a wide variety of symposia, CE, and special events for optometrists, residents, and students.

Maggie Cline, MPH, initially joined the organization in 2022 and served as Executive Director Utah.

This year's meeting is taking place from June 25-28 in Minneapolis, Minnesota.

Aldeyra resubmits NDA for reproxalap, aiming to address FDA concerns and demonstrate efficacy in treating dry eye disease symptoms.